British–Swedish AstraZeneca's Tagrisso product provides a significant benefit in the treatment of epidermal growth factor receptor (EGFR) T790M mutation-positive metastatic non-small cell lung cancer, according to a phase three clinical trial, it was reported on Wednesday.
Results from the first randomised Phase III data indicated that the product decreased the risk of lung cancer progression by 70% compared to chemotherapy and improved progression-free survival by about six months.
In a pre-specified exploratory subgroup analysis in patients with central nervous system metastases, PFS in the Tagrisso group was 8.5 months compared with 4.2 with platinum-pemetrexed chemo in 34% of patients. The safety profile of Tagrisso was similar to earlier studies.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study